Science and Research

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was -125.4 mL/year (95% CI -168.1 to -82.7) in the nintedanib group and -189.7 mL/year (95% CI -229.8 to -149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.

  • Richeldi, L.
  • Kreuter, M.
  • Selman, M.
  • Crestani, B.
  • Kirsten, A. M.
  • Wuyts, W. A.
  • Xu, Z.
  • Bernois, K.
  • Stowasser, S.
  • Quaresma, M.
  • Costabel, U.

Keywords

  • idiopathic pulmonary fibrosis
  • Ingelheim for being a coprincipal investigator and member of the steering
  • committee for the INPULSIS trials
  • grants and personal fees for being an advisory
  • board member from InterMune
  • personal fees from MedImmune, Roche and Takeda for
  • being an advisory board member
  • consulting fees from Biogen Idec, Celgene,
  • ImmuneWorks, Pliant Therapeutics and Sanofi-Aventis
  • speaker honoraria from
  • Shionogi. MK reports receipt of grants and personal fees from Boehringer
  • Ingelheim, InterMune and Roche. MS reports receipt of personal fees from
  • Boehringer Ingelheim for being a member of the INPULSIS steering committee. BC
  • reports receipt of grants, personal fees and non-financial support from
  • Boehringer Ingelheim and InterMune
  • personal fees and non-financial support from
  • Sanofi
  • grants from Cardif and MedImmune
  • and personal fees from AstraZeneca.
  • A-MK reports receipt of grants (paid to her institution) and lecture fees from
  • Boehringer Ingelheim. WAW reports receipt of grants (paid to his institution)
  • from InterMune and travel costs for congresses from Boehringer Ingelheim, Roche
  • and Bayer. ZX reports no competing interests. KB, SSt and MQ are employees of
  • Boehringer Ingelheim. UC reports receipt of grants (paid to his institution)
  • personal fees for consulting and lecture fees from Boehringer Ingelheim,
  • InterMune and Bayer
  • and personal fees for consulting from AstraZeneca, Biogen,
  • Centocor, FibroGen, Gilead, GlaxoSmithKline, Roche and UCB Celltech.
Publication details
DOI: 10.1136/thoraxjnl-2016-209701
Journal: Thorax
Pages: 581-583 
Number: 6
Work Type: Original
Location: ARCN, TLRC
Disease Area: DPLD
Partner / Member: Ghd, Thorax
Access-Number: 28993537
See publication on PubMed

DZL Engagements

chevron-down